NBMBX
Price
$15.23
Change
+$0.15 (+0.99%)
Updated
Aug 21 closing price
Net Assets
2.23B
PMBJX
Price
$38.66
Change
+$0.31 (+0.81%)
Updated
Aug 21 closing price
Net Assets
23.18B
Interact to see
Advertisement

NBMBX vs PMBJX

NBMBX vs PMBJX Comparison Chart in %
View a ticker or compare two or three
VS
NBMBX vs. PMBJX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBMBX is a Hold and PMBJX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
PMBJX has more cash in the bank: 23.2B vs. NBMBX (2.23B). NBMBX (0.00) and PMBJX (0.00) have matching dividends . NBMBX was incepted earlier than PMBJX: NBMBX (30 years) vs PMBJX (25 years). NBMBX (1.18) is less costly to investors than PMBJX (0.76). NBMBX is a more actively managed with annual turnover of: 144.00 vs. PMBJX (13.70). NBMBX has a lower initial minimum investment than PMBJX: NBMBX (0) vs PMBJX (1000). PMBJX annual gain was more profitable for investors over the last year : -10.41 vs. NBMBX (-18.65). PMBJX return over 5 years is better than : -1.32 vs. NBMBX (-32.05).
NBMBXPMBJXNBMBX / PMBJX
Total Expense Ratio1.180.76155%
Annual Report Gross Expense Ratio1.180.76155%
Fund Existence30 years25 years-
Gain YTD4.101-0.745-551%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets2.23B23.2B10%
Annual Yield % from dividends0.000.00-
Returns for 1 year-18.65-10.41179%
Returns for 3 years7.8320.1739%
Returns for 5 years-32.05-1.322,431%
Returns for 10 years12.4079.6716%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPXX19.080.09
+0.47%
Nuveen S&P 500 Dynamic Overwrite Fund
FBDC17.67N/A
-0.01%
FT Confluence BDC & SpecialtyFinacIncETF
CALI50.38-0.01
-0.03%
iShares Short-Term CA Muni Act ETF
WEA10.43-0.05
-0.48%
Western Asset Premier
BIS10.82-0.30
-2.70%
ProShares UltraShort Nasdaq Biotech